

Charles River manages 2.9% growth in Q2, 2013

August 1, 2013 | Company results | By BioSpectrum Bureau



Singapore: Drug development company Charles River Laboratories has marked net sales of \$292.9 million in the second quarter of 2013, maintaining growth of 2.9 percent from \$284.7 million in the second quarter of 2012.

"Based on our second-quarter results, we are reaffirming our sales and non-GAAP earnings per share guidance for 2013. We remain intently focused on our efforts to drive sales growth across all client segments and improve operating efficiency in order to enhance shareholder value," the company said.

Mr James C Foster, chairman, president and CEO, said, "We were pleased with our second-quarter results. We implemented actions to position the Company as the partner of choice for early-stage drug discovery and development, initiated targeted sales efforts which have enabled us to gain market share, and expanded our portfolio through strategic acquisitions. The benefit of these actions is clear in our second quarter results, and will drive revenue and earnings per share growth in 2013 and beyond."

Mr Foster continued, "Based on our second-quarter results, we are reaffirming our sales and non-GAAP earnings per share guidance for 2013. We remain intently focused on our efforts to drive sales growth across all client segments and improve operating efficiency in order to enhance shareholder value."